Cross-Linked Dependency of Boronic Acid-Conjugated Chitosan Nanoparticles by Diols for Sustained Insulin Release

被引：22

作者：

Siddiqui, Nabil A. ^{[1
]}

Billa, Nashiru ^{[1
]}

Roberts, Clive J. ^{[2
]}

Osei, Yaa Asantewaa ^{[3
]}

机构：

[1] Univ Nottingham, Sch Pharm, Malaysia Campus,Jalan Broga, Semenyih 43500, Selangor Darul, Malaysia

[2] Univ Nottingham, Sch Pharm, Univ Pk, Nottingham NG7 2RD, England

[3] Kwame Nkrumah Univ Sci & Technol, Fac Pharm & Pharmaceut Sci, Kumasi, Ghana

来源：

PHARMACEUTICS | 2016年 / 8卷 / 04期

关键词：

stimuli-responsive; glucose; fructose; drug delivery; nanoparticles; POLYELECTROLYTE NANOCOMPLEXES; GRAFTED CHITOSAN; DELIVERY SYSTEMS; DERIVATIVES;

D O I：

10.3390/pharmaceutics8040030

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Boronic acids have been widely investigated for their potential use as glucose sensors in glucose responsive polymeric insulin delivery systems. Interactions between cyclic diols and boronic acids, anchored to polymeric delivery systems, may result in swelling of the delivery system, releasing the drug. In this study, 4-formylphenylboronic acid conjugated chitosan was formulated into insulin containing nanoparticles via polyelectrolyte complexation. The nanoparticles had an average diameter of 140 +/- 12.8 nm, polydispersity index of 0.17 +/- 0.1, zeta potential of + 19.1 +/- 0.69 mV, encapsulation efficiency of 81% +/- 1.2%, and an insulin loading capacity of 46% +/- 1.8% w/w. Changes in size of the nanoparticles and release of insulin were type of sugar-and concentration-dependent. High concentration of diols resulted in a sustained release of insulin due to crosslink formation with boronic acid moieties within the nanoparticles. The formulation has potential to be developed into a self-regulated insulin delivery system for the treatment of diabetes.

引用

页数：11

共 34 条

[1]

Asantewaa Y, 2013, PHARMACEUTICS, V5, P69

[2]

Barbas AS, 2010, FUTURE ONCOL, V6, P1117, DOI [10.2217/fon.10.67, 10.2217/FON.10.67]

[3]

Berenson D, 2011, ANN NY ACAD SCI, V1243, P40

[4]

Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities [J].

Chiu, Gigi N. C. ;

Wong, Man-Yi ;

Ling, Leong-Uung ;

Shaikh, Ishaque M. ;

Tan, Kuan-Boone ;

Chaudhury, Anumita ;

Tan, Bee-Jen .

CURRENT DRUG METABOLISM, 2009, 10 (08) :861-874

[5]

Clogston JD, 2011, METHODS MOL BIOL, V697, P63, DOI 10.1007/978-1-60327-198-1_6

[6]

Dvir T, 2011, NAT NANOTECHNOL, V6, P13, DOI [10.1038/nnano.2010.246, 10.1038/NNANO.2010.246]

[7]

Preparation of insulin nanoparticles and their encapsulation with biodegradable polyelectrolytes via the layer-by-layer adsorption [J].

Fan, Y. F. ;

Wang, Y. N. ;

Fan, Y. G. ;

Ma, J. B. .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 324 (02) :158-167

[8]

Enhancement of nasal absorption of insulin using chitosan nanoparticles [J].

Fernández-Urrusuno, R ;

Calvo, P ;

Remuñán-López, C ;

Vila-Jato, JL ;

Alonso, MJ .

PHARMACEUTICAL RESEARCH, 1999, 16 (10) :1576-1581

[9]

Chitosan nanoparticles as delivery systems for doxorubicin [J].

Janes, KA ;

Fresneau, MP ;

Marazuela, A ;

Fabra, A ;

Alonso, MJ .

JOURNAL OF CONTROLLED RELEASE, 2001, 73 (2-3) :255-267

[10]

Peroral delivery of insulin using chitosan derivatives: A comparative study of polyelectrolyte nanocomplexes and nanoparticles [J].

Jintapattanakit, Anchalee ;

Junyaprasert, Varaporn B. ;

Mao, Shirui ;

Sitterberg, Johannes ;

Bakowsky, Udo ;

Kissel, Thomas .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 342 (1-2) :240-249

← 1 2 3 4 →